Inhibition of Type 1 Immunity with Tofacitinib Is Associated with Marked Improvement in Longstanding Sarcoidosis

Sarcoidosis is an idiopathic inflammatory disorder that is commonly treated with glucocorticoids. In this open-label trial, ten patients with cutaneous sarcoidosis were treated with tofacitinib, a Janus kinase inhibitor.